Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2013; 121(05): 255-261
DOI: 10.1055/s-0032-1333233
DOI: 10.1055/s-0032-1333233
Review
Interactions of the IGF System with Diabetes and its Vascular Complications
R. P. Narayanan
1
Vascular Research Group, Institute of Population Health, The University of Manchester, Manchester, United Kingdom
,
K. W. Siddals
1
Vascular Research Group, Institute of Population Health, The University of Manchester, Manchester, United Kingdom
,
A. H. Heald
1
Vascular Research Group, Institute of Population Health, The University of Manchester, Manchester, United Kingdom
2
Department of Medicine, Leighton Hospital, United Kingdom
,
J. M. Gibson
1
Vascular Research Group, Institute of Population Health, The University of Manchester, Manchester, United Kingdom
3
Department of Diabetes and Endocrinology, Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom
› Author Affiliations
Further Information
Publication History
received 30 August 2012
first decision 04 December 2012
accepted 18 December 2012
Publication Date:
21 February 2013 (online)
Abstract
The insulin-like growth factor (IGF) system is an evolutionarily conserved group of important proteins that are fundamental to life. Indeed, insulin can be viewed as simply a specialized arm of the IGF system that has evolved to regulate primarily metabolic functions. The main purpose of the IGF system is to form a highly refined mechanism for the control of cellular growth, metabolism and survival. Dysregulation of such a system can have serious consequences. In this review we have focussed on the IGF system and its relation to diabetes and the development of cardiometabolic disorders.
-
References
- 1 Lu C, Lam H, Menon R. New members of the insulin family: regulators of metabolism, growth and now… reproduction. Pediatric Research 2005; 57: 70R-73R
- 2 Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995; 16: 3-34
- 3 Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews 1999; 20: 761-787
- 4 Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997; 18: 801-831
- 5 Juul A, Holm K, Kastrup KW et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. Journal of Clinical Endocrinology & Metabolism 1997; 82: 2497-2502
- 6 Tekcan D, Bas F, Atalar F et al. No effect of the IGF-1 gene rs35767 and rs17032362 polymorphisms in the etiology of idiopathic short stature. Experimental & Clinical Endocrinology & Diabetes 2012; 120: 395-400
- 7 Friedrich N, Jorgensen T, Juul A et al. Insulin-like growth factor I and anthropometric parameters in a Danish population. Experimental & Clinical Endocrinology & Diabetes 2012; 120: 171-174
- 8 Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Reviews 1989; 10: 68-91
- 9 Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Progress in Growth Factor Research 1991; 3: 243-266
- 10 Bunn RC, Fowlkes J. Insulin-like growth factor binding protein proteolysis. Trends in endocrinology and metabolism 2003; 14: 176-181
- 11 Roghani M, Lassarre C, Zapf J et al. Two Insulin-Like Growth Factor (IGF)-Binding Proteins Are Responsible for the Selective Affinity for IGF-II of Cerebrospinal Fluid Binding Proteins. Journal of Clinical Endocrinology & Metabolism 1991; 73: 658-666
- 12 Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 2002; 23: 824-854
- 13 Fu P, Thompson JA, Bach LA. Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. Journal of Biological Chemistry 2007; 282: 22298-22306
- 14 Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends in Endocrinology and Metabolism 2009; 20: 153-162
- 15 Perks CM, Newcomb PV, Norman MR et al. Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. Journal of molecular endocrinology 1999; 22: 141-150
- 16 Brismar K, Fernqvist-Forbes E, Wahren J et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. Journal of Clinical Endocrinology & Metabolism 1994; 79: 872-878
- 17 Powell DR, Suwanichkul A, Cubbage ML et al. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. The Journal of biological chemistry 1991; 266: 18868-18876
- 18 Snyder DK, Clemmons DR. Insulin-Dependent Regulation of Insulin-Like Growth Factor-Binding Protein-1. Journal of Clinical Endocrinology & Metabolism 1990; 71: 1632-1636
- 19 Unterman TG, Oehler DT, Murphy LJ et al. Multihormonal regulation of insulin-like growth factor-binding protein-1 in rat H4IIE hepatoma cells: the dominant role of insulin. Endocrinology 1991; 128: 2693-2701
- 20 Hilding A, Brismar K, Thoren M et al. Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 1993; 77: 1142-1147
- 21 Fernqvist Forbes E, Hilding A, Ekberg K et al. Influence of circulating epinephrine and norepinephrine on insulin-like growth factor binding protein-1 in humans. The Journal of clinical endocrinology and metabolism 1997; 82: 2677-2680
- 22 Lewitt M, Hall K, Bang P et al. Altered response of insulin-like growth factor-binding protein 1 to nutritional deprivation in type 2 diabetes mellitus. Metabolism, clinical and experimental 2005; 54: 275-280
- 23 Kotronen A, Lewitt M, Hall K et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. Journal of Clinical Endocrinology & Metabolism 2008; 93: 4867-4872
- 24 Lewitt MS, Hilding A, Ostenson CG et al. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008; 51: 1135-1145
- 25 Lewitt MS, Hilding A, Brismar K et al. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. European Journal of Endocrinology 2010; 163: 233-242
- 26 Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001; 44: 333-339
- 27 Sandhu MS, Heald AH, Gibson JM et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745
- 28 Wallander M, Brismar K, Ohrvik J et al. Insulin-like growth factor I: A predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 2006; 49: 2247-2255
- 29 Deleskog A, Hilding A, Brismar K et al. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. Diabetologia 2012; 55: 1668-1678
- 30 Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001; 44: 333-339
- 31 Petersson U, Ostgren CJ, Brudin L et al. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Soderakra Cardiovascular Risk Factor Study. Diabetes & Metabolism 2009; 35: 198-205
- 32 Heald AH, Sharma R, Anderson SG et al. Dietary intake and the insulin-like growth factor system: Effects of migration in two related populations in India and Britain with markedly different dietary intake. Public Health Nutrition 2005; 8: 620-627
- 33 Claudio M, Benjamim F, Riccardo B et al. Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity 2010; 18: 2055-2077
- 34 Heald AH, Kaushal K, Siddals KW et al. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology and Diabetes 2006; 114: 371-376
- 35 Teppala S, Shankar A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care 2010; 33: 2257-2259
- 36 Rajpathak SN, McGinn AP, Strickler HD et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone & IGF Research 2008; 18: 166-173
- 37 Yeap . IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men. European journal of endocrinology Supplement 162: 249-257
- 38 Schneider H, Friedrich N, Klotsche J et al. Prediction of incident diabetes mellitus by baseline IGF1 levels. European Journal of Endocrinology 2011; 164: 223-229
- 39 Grissa O, Yessoufou A, Mrisak I et al. Growth factor concentrations and their placental mRNA expression are modulated in gestational diabetes mellitus: Possible interactions with macrosomia. BMC Pregnancy and Childbirth 2010; 10
- 40 Moses AC, Young SC, Morrow LA et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91-100
- 41 Clemmons DR, Moses AC, Sommer A et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Hormone & IGF Research 2005; 15: 265-274
- 42 Succurro E, Andreozzi F, Sciaqua A et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with Cardiometabolic risk factors in nondiabetic subjects. Diabetes Care 2008; 31: 1886-1888
- 43 Schernhammer ES, Tworoger SS, Eliassen AH et al. Body shape throughout life and correlations with IGFs and GH. Endocrine-Related Cancer 2007; 14: 721-732
- 44 Crowe FL, Key TJ, Allen NE et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Human Biology 2011; 38: 194-202
- 45 Heald AH, Karvestedt L, Anderson SG et al. Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes. American Journal of Medicine 119: (167) e169-167.e115
- 46 Frystyk J, Skjærbæk C, Vestbo E et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of Type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999; 15: 314-322
- 47 O’Dell SD, Miller GJ, Cooper JA et al. Apal polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males. International Journal of Obesity & Related Metabolic Disorders 1997; 21: 822-825
- 48 Rodriguez S, Gaunt TR, Dennison E et al. Replication of IGF2-INS-TH*5 haplotype effect on obesity in older men and study of related phenotypes. European Journal of Human Genetics 2006; 14: 109-116
- 49 Siddals KW, Westwood M, Gibson JM et al. IGF-binding protein-1 inhibits IGF effects on adipocyte function: implications for insulin-like actions at the adipocyte. Journal of Endocrinology 2002; 174: 289-297
- 50 Wheatcroft . IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007; 56: 285-294
- 51 Reinehr T, Panteliadou A, de Sousa G et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and growth in obese children before and after reduction of overweight. Journal of Pediatric Endocrinology 2009; 22: 225-233
- 52 Tivesten Ã, Bollano E, Andersson I et al. Liver-Derived Insulin-Like Growth Factor-I Is Involved in the Regulation of Blood Pressure in Mice. Endocrinology 2002; 143: 4235-4242
- 53 Capoluongo . Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine 2006; 34: 303-311
- 54 Zhang L, Curhan GC, Forman JP. Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women. Journal of Hypertension 2011; 29: 229-235
- 55 Heald AH, Siddals KW, Fraser W et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51: 2629-2636
- 56 Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome – a study in borderline hypertension. Blood Pressure 1998; 7: 89-95
- 57 Zandbergen AAM, Lamberts SWJ, Baggen MGA et al. The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: A randomized clinical trial. Clinical Endocrinology 2006; 64: 203-208
- 58 Onder G, Liperoti R, Russo A et al. Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study. European Journal of Clinical Pharmacology 2007; 63: 389-395
- 59 Cooley SM, Donnelly JC, Geary MP et al. Maternal insulin-like growth factors 1 and 2 (IGF-1, IGF-2) and IGF BP-3 and the hypertensive disorders of pregnancy. Journal of Maternal-Fetal & Neonatal Medicine 2004; 23: 658-661
- 60 Faienza MF, Santoro N, Lauciello R et al. IGF2 gene variants and risk of hypertension in obese children and adolescents. Pediatric Research 2010; 67: 340-344
- 61 Colao A, Spiezia S, Di Somma C et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. Journal of Endocrinological Investigation 2005; 28: 440-448
- 62 Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology 2008; 69: 347-358
- 63 Siddals KW, Allen J, Sinha S et al. Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization. Journal of Biological Chemistry 2011; 286: 16623-16630
- 64 Martin RM, Gunnell D, Whitley E et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. Journal of Clinical Endocrinology & Metabolism 2008; 93: 1331-1338
- 65 Ruotolo G, Bavenholm P, Brismar K et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. Journal of the American College of Cardiology 2000; 35: 647-654
- 66 Boquist S, Ruotolo G, Skoglund-Andersson C et al. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clinical Endocrinology 2008; 68: 51-58
- 67 Wang J, Razuvaev A, Folkersen L et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 2012; 220: 102-109
- 68 Juul A, Scheike T, Davidsen M et al. Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic Heart Disease. Circulation 2002; 106: 939-944
- 69 Kaplan RC, McGinn AP, Pollak MN et al. Association of Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1), and IGFBP-3 Levels with Incident Coronary Events and Ischemic Stroke. Journal of Clinical Endocrinology & Metabolism 2007; 92: 1319-1325
- 70 Laughlin GA, Barrett-Connor E, Criqui MH et al. The Prospective Association of Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-1 Levels with All Cause and Cardiovascular Disease Mortality in Older Adults: The Rancho Bernardo Study. Journal of Clinical Endocrinology & Metabolism 2004; 89: 114-120
- 71 Vasan RS, Sullivan LM, D’Agostino RB et al. Serum Insulin-like Growth Factor I and Risk for Heart Failure in Elderly Individuals without a Previous Myocardial Infarction: The Framingham Heart Study. Annals of Internal Medicine 2003; 139: 642-648
- 72 Schwab S, Spranger M, Krempien S et al. Plasma Insulin-like Growth Factor I and IGF Binding Protein 3 Levels in Patients With Acute Cerebral Ischemic Injury. Stroke 1997; 28: 1744-1748
- 73 Denti L, Annoni V, Cattadori E et al. Insulin-like growth factor 1as a predictor of ischemic stroke outcome in the elderly. The American journal of medicine 2004; 117: 312-317
- 74 Spilcke-Liss E, Friedrich N, Dorr M et al. Serum insulin-like growth factor i and its binding protein 3 in their relation to intima-media thickness: Results of the study of health in Pomerania (SHIP). Clinical Endocrinology 2011; 75: 70-75
- 75 Schneider HJ, Klotsche J, Saller B et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6 773 primary care patients. European Journal of Endocrinology 2008; 158: 153-161
- 76 Galoiu S, Jurcut R, Vladaia A et al. Structural and functional changes of carotid wall properties in patients with acromegaly are not restored after 1 year of GH/IGF1 normalization. Experimental & Clinical Endocrinology & Diabetes 2012; 120: 238-243
- 77 Page JH, Ma J, Pollak M et al. Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clinical Chemistry 2008; 54: 1682-1688
- 78 Brugts MP, van den Beld AW, Hofland LJ et al. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. Journal of Clinical Endocrinology & Metabolism 2008; 93: 2515-2522
- 79 Friedrich N, Schneider H, Dorr M et al. All-cause mortality and serum insulin-like growth factor I in primary care patients. Growth Hormone and IGF Research 2011; 21: 102-106
- 80 van Bunderen CC, van Nieuwpoort IC, van Schoor NM et al. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. Journal of Clinical Endocrinology & Metabolism 2010; 95: 4616-4624
- 81 Colao A, Ferone D, Marzullo P et al. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews 2004; 25: 102-152
- 82 Stochholm K, Christiansen J, Laursen T et al. Mortality and Reduced Growth Hormone Secretion. Hormone Research in Paediatrics 2007; 68: 173-176
- 83 LeRoith D. IGF-I: Panacea or Poison?. Journal of Clinical Endocrinology & Metabolism 2010; 95: 4549-4551
- 84 Heald AH, Siddals KW, Fraser W et al. Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes. Diabetes 2002; 51: 2629-2636
- 85 Rajpathak SN, McGinn AP, Strickler HD et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone and IGF Research 2008; 18: 166-173
- 86 Clemens A, Klevesath MS, Hofmann M et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 1999; 48: 1236-1240
- 87 Teppala S, Shankar A, Sabanayagam C. Association between IGF-1 and chronic kidney disease among US adults. Clinical and experimental nephrology 2010; 14: 440-444
- 88 Frystyk J, Ivarsen P, Skjaerbaek C et al. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999; 56: 2076-2084
- 89 Akturk M, Arslan M, Altinova A et al. Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus. Growth Hormone & Igf Research 2007; 17: 186-193
- 90 Stephens RH, McElduff P, Heald AH et al. Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes 2005; 54: 3547-3553
- 91 Hovind P, Lamberts S, Hop W et al. An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. European Journal of Endocrinology 2007; 156: 83-90
- 92 Narayanan RP, Fu B, Heald AH et al. IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes. Endocrine Connections 2012; 1: 95-102
- 93 Meyer Schwickerath R, Pfeiffer A, Blum WF et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. The Journal of clinical investigation 1993; 92: 2620-2625
- 94 Waldbillig RJ, Jones BE, Schoen TJ et al. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Current Eye Research 1994; 13: 539-546
- 95 Poulaki V, Joussen AM, Mitsiades N et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. American Journal of Pathology 2004; 165: 457-469
- 96 Haurigot V, Villacampa P, Ribera A et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. Journal of Biological Chemistry 2009; 284: 22961-22969
- 97 Payne JF, Tangpricha V, Cleveland J et al. Serum insulin-like growth factor-I in diabetic retinopathy. Molecular Vision 2011; 17: 2318-2324
- 98 Amemiya T, Toibana M, Hashimoto M et al. Diabetic retinopathy in acromegaly. Ophthalmologica 1978; 176: 74-80
- 99 Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). European Journal of Endocrinology 2004; 151: 103-106
- 100 Janssen JAMJL, Jacobs ML, Derkx FHM et al. Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism 1997; 82: 2809-2815
- 101 Frystyk J, Bek T, Flyvbjerg A et al. The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients. Diabetic Medicine 2003; 20: 269-276
- 102 Ringholm L, Vestgaard M, Laugesen CS et al. Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes. Growth Hormone and IGF Research 2011; 21: 25-30
- 103 Meyer-Schwickerath R, Pfeiffer A, Blum WF et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. The Journal of clinical investigation 1993; 92: 2620-2625
- 104 Ishii DN, Lupien SB. Insulin-like growth factor replacement therapy for diabetic neuropathy: experimental basis. [Review] [119 refs] 2003; 4: 257-269
- 105 Zhuang H-X, Snyder CK, Pu S-F et al. Insulin-like Growth Factors Reverse or Arrest Diabetic Neuropathy: Effects on Hyperalgesia and Impaired Nerve Regeneration in Rats. Experimental Neurology 1996; 140: 198-205
- 106 Gao W-Q, Shinsky N, Ingle G et al. IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment. Journal of Neurobiology 1999; 39: 142-152
- 107 Karvestedt L, Martensson E, Grill V et al. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009; 32: 317-322